Tongeye Medical Technology (Ningbo) Co., Ltd. was established in October 2023, focusing mainly on the development and production of cell therapy drugs for ophthalmic diseases. In November, the company completed its angel round of financing. The company has multiple research and development pipelines. Among them, the key project of transplanting unique youthful RPE cells derived from iPSCs for the treatment of dry retinal degeneration has achieved significantly better therapeutic effects in animal models compared with other reported RPE cells. The established highly efficient induction and differentiation method with independent intellectual property rights has shortened the traditional differentiation cycle from 120 to 150 days to just 25 days, significantly reducing costs and improving accessibility. This brings hope for vision improvement to hundreds of millions of patients with dry retinal degeneration worldwide.
